Significant biosimilar activities this week include 01 May 2020 | AbbVie released its Q1 2020 financial results,...
Pearce IP BioBlast™: w/e 08 May 2020
read more
Home / News / Pearce IP Blog
ALL BLOGS BY
Naomi Pearce
Naomi is listed in IAM Patent 1000 as one of Australia's leading patent litigators. Underpinning Naomi’s legal work is a deep understanding of the pharma/biopharma industries, resulting from first hand experience and knowledge as VP of IP in-house at global pharma giants, and Partner of a top-tier international law firm.
See Naomi's full profile
Pearce IP BioBlast™: w/e 01 May 2020
Significant biosimilar activities this week include 23 April 2020 | Henlius Biotech announced it has received two EU...
Pearce IP BioBlast™: w/e 24 Apr 2020
Significant biosimilar activities this week include 21 Apr 20 | The Centre for Biosimilars reported that Xbrane Pharma...
Pearce IP BioBlast™: w/e 17 Apr 2020
Significant biosimilar activities this week include 14 April 20 | Mylan and Biocon launched Fulphila® (pegfilgrastim)...
Pearce IP BioBlast™: w/e 10 Apr 2020
Significant biosimilar activities this week include March 20 | BiosanaPharma released the results of Ph I trials of...
Pearce IP BioBlast™: w/e 03 Apr 2020
Significant biosimilar activities this week include 30 Mar 20 | Biocad announced it had received registration...
Pearce IP BioBlast™: w/e 27 March 2020
Significant biosimilar activities this week include March 20 | The UK High Court ruled filing errors in a...
Pearce IP BioBlast™: w/e 20 March 2020
Significant biosimilar activities this week include 16 Mar 20 | Teva and Celltrion launched Herzuma (trastuzumab) in...
Centre for Biosimilars reports biosimilar bills introduced to US Congress
On 19 March 2020, the Centre for Biosimilars reported on a pair of biosimilar bills which were introduced to the US...
Pearce IP BioBlast™: w/e 13 March 2020
Significant biosimilar activities this week include 09 Mar 20 | The FDA and FTC held a public workshop to further...
Pearce IP BioBlast™: w/e 06 March 2020
Significant biosimilar activities this week include 02 Mar 20 | Celltrion launched Remsima SC, its subcutaneous...
Pearce IP BioBlast™: w/e 28 February 2020
Significant biosimilar activities this week include 24 Feb 20 | The FDA launched a searchable version of the 'Purple...
Pfizer announces hestitance to launch Amsparity in EU
Despite receiving CHMP approval earlier this month, Pfizer has announced it does not currently plan to launch...
Harbour BioMed receives FDA approval of Investigational New Drug application
On 28 February 2020, Harbour BioMed announced FDA approval of its Investigational New Drug application for HBM4003, an...
Mark Your Calendars: The End of the AU Innovation Patent System is Set
As we previously foreshadowed, the innovation patent system has been given its end dates: 25 August 2021: last date to...
Pearce IP BioBlast™: w/e 21 February 2020
Significant biosimilar activities this week include 12 Feb 20 | Wockhardt announced divestment of assets to Dr...